BioNTech SE Updates on Penn Discussions

TL;DR

BioNTech still talking to Penn about IP, no major news yet.

AI Summary

BioNTech SE is providing an update on its ongoing discussions with the University of Pennsylvania (Penn) regarding intellectual property matters. The company previously disclosed these discussions, which are part of its ongoing operations and legal proceedings.

Why It Matters

This filing indicates ongoing legal or licensing discussions between BioNTech and a major academic institution, which could impact future intellectual property rights and collaborations.

Risk Assessment

Risk Level: medium — Ongoing discussions with a university about intellectual property can carry risks related to licensing, litigation, or future development rights.

Key Players & Entities

• BioNTech SE (company) — Registrant
• University of Pennsylvania (company) — Party in discussions
• Penn (company) — Abbreviation for University of Pennsylvania

FAQ

From the Filing

0001776985-24-000070.txt : 20240807 0001776985-24-000070.hdr.sgml : 20240807 20240806192045 ACCESSION NUMBER: 0001776985-24-000070 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240806 FILED AS OF DATE: 20240807 DATE AS OF CHANGE: 20240806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 241180961 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190840 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 form6-kupenn6aug2024.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF AUGUST 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐ INFORMATION INCLUDED AS PART OF THIS FORM 6-K BioNTech SE (the “Company”) previously disclosed that it was in discussions with the University of Pennsylvania (“Penn”) concerning royalties and other amounts allegedly owed on sales of the Company’s COVID-19 vaccine since commercialization. On August 5, 2024, Penn filed a lawsuit against the Company and its former subsidiary, BioNTech RNA Pharmaceuticals GmbH, in the U.S. District Court for the Eastern District of Pennsylvania (Civil Action No. 2:24-cv-3801 The Trustees of the University of Pennsylvania v. BioNTech SE and BioNTech RNA Pharmaceuticals GmbH) in connection with this dispute. The Company intends to vigorously defend against all allegations in the complaint. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By: /s/ Jens Holstein By: /s/ Dr. Sierk Poetting Name: Jens Holstein Name: Dr. Sierk Poetting Title: Chief Financial Officer Title: Chief Operating Officer Date: August 6, 2024